Solid Biosciences Inc. (SLDB) financial statements (2022 and earlier)

Company profile

Business Address 141 PORTLAND STREET, FIFTH FLOOR
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments207,779229,760248,959268,497154,74424,79740,441
Cash and cash equivalents119,136109,676200,609268,497154,74424,79740,441
Short-term investments88,643120,08448,350    
Restricted cash and investments 9090    
Receivables110594286280   
Other undisclosed current assets14,7238,3665,7435,5184,1572,3653,094
Total current assets:222,612238,810255,078274,295158,90127,16243,535
Noncurrent Assets
Operating lease, right-of-use asset1,1421,2181,5813,1963,5793,9514,310
Property, plant and equipment6,4626,8867,1287,4618,1538,8699,582
Restricted cash and investments2,0702,0722,070327327327327
Other noncurrent assets94   209209209
Total noncurrent assets:9,76810,17610,77910,98412,26813,35614,428
TOTAL ASSETS:232,380248,986265,857285,279171,16940,51857,963
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,99112,15110,7179,98811,91412,63311,108
Accounts payable4,4634,1483,0033,1943,2744,0832,793
Accrued liabilities9,5288,0037,7146,7948,6408,5508,315
Deferred revenue8,0808,86510,04810,66210,359  
Debt232226220214208202197
Other liabilities357361    
Other undisclosed current liabilities1,2631,2271,4991,9651,9991,9301,863
Total current liabilities:23,60122,54222,54522,82924,48014,76513,168
Noncurrent Liabilities
Long-term debt and lease obligation5688211,0682,4492,9443,5224,082
Finance lease, liability293353412469525579632
Operating lease, liability2754686561,9802,4192,9433,450
Liabilities, other than long-term debt 2,2604,3067,00111,659  
Deferred revenue 2,2604,3067,00110,359  
Other liabilities    1,300  
Other undisclosed noncurrent liabilities(275)    (2,943)(3,450)
Total noncurrent liabilities:2933,0815,3749,45014,6033,5224,082
Total liabilities:24,16925,62327,91932,27939,08318,28717,250
Stockholders' equity
Stockholders' equity attributable to parent208,211223,363237,938253,000132,08622,23140,713
Common stock112112112112874848
Additional paid in capital684,901681,420678,001674,357536,568405,389402,625
Accumulated other comprehensive loss(45)(22)(11)    
Accumulated deficit(476,757)(458,147)(440,164)(421,469)(404,569)(383,206)(361,960)
Total stockholders' equity:208,211223,363237,938253,000132,08622,23140,713
TOTAL LIABILITIES AND EQUITY:232,380248,986265,857285,279171,16940,51857,963

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues3,1543,5373,5943,335   
Revenue from related parties 3,5373,5943,335   
Gross profit:3,1543,5373,5943,335   
Operating expenses(21,806)(21,568)(22,279)(20,221)(21,347)(21,226)(18,974)
Operating loss:(18,652)(18,031)(18,685)(16,886)(21,347)(21,226)(18,974)
Nonoperating income (expense)4248(10)(14)(16)(20)(13)
Other nonoperating income  3    
Net loss available to common stockholders, diluted:(18,610)(17,983)(18,695)(16,900)(21,363)(21,246)(18,987)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(18,610)(17,983)(18,695)(16,900)(21,363)(21,246)(18,987)
Other undisclosed comprehensive income (loss)(23)(11)(11)   1
Comprehensive loss, net of tax, attributable to parent:(18,633)(17,994)(18,706)(16,900)(21,363)(21,246)(18,986)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: